PerkinElmer Inc Stock News

Parkland Corporation (OTCPK:PKIUF) Q3 2022 Results Conference Call November 3, 2022 8:30 AM ET Company Participants Valerie Roberts - Director, Investor Relations Bob Espey - President and CEO Marcel

PerkinElmer (PKI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PerkinElmer (PKI) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Many S&P 500 investors are still hiding from the bear. But some are stepping in front of what they think is a moneymaking moment.

PerkinElmer said Monday it expects organic sales and adjusted profit to top its previous third-quarter expectations, and PKI stock jumped. The post PerkinElmer Sweetens Its Outlook And Shares Surge, B

Mettler-Toledo, PerkinElmer and Waters have been highlighted in this Industry Outlook article.

The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD), Waters (WAT) and PerkinElmer (PKI) are gaining from strong life science, pharmaceutical and academic end-market dema

The Zacks Instruments - Scientific industry participants like Mettler-Toledo (MTD), Waters (WAT) and PerkinElmer (PKI) are gaining from strong life science, pharmaceutical and academic end-market dema

PerkinElmer (NYSE:PKI) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 1 4 3 0 Last 30D 0 0

BD's (BDX) latest launch is expected to provide scientists with an integrated ecosystem that enables optimization of panel design, collaboration and analysis.

PerkinElmer's (PKI) latest launch is expected to enable researchers to multiplex and perform immunophenotyping and viability assays in a lesser time with a simplified user interface.

PerkinElmer's (PKI) latest launch is expected to enable researchers to multiplex and perform immunophenotyping and viability assays in a lesser time with a simplified user interface.

Investors love to see steady increases in sales and profit estimates, but these have been declining for most sectors.

PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.

PerkinElmer's (PKI) T-Cell Select reagent kit is expected to allow for a more automated workflow following the FDA's approval.